You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 302 No. 7, August 19, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Informatics/ Internet in Medicine
 •Medical Informatics
 •Quality of Care
 •Evidence-Based Medicine
 •Statistics and Research Methods
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Registries for Robust Evidence

Nancy A. Dreyer, PhD; Sarah Garner, PhD

JAMA. 2009;302(7):790-791.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although randomized clinical trials (RCTs) are the bedrock for establishing which interventions are efficacious, there is increasing recognition that they cannot address all needs, especially the need to determine, in a timely manner, the safety and effectiveness of different interventions used in the diverse array of patients and settings that make up a health care system. Interest has increased in the role of observational studies, and more specifically in registries and other electronic data sets, as a way to fill these critical gaps in evidence and as useful guides for helping to determine formulary placement. The recently released "highest priority challenge topics" from the National Institutes of Health (NIH) pointedly reference registries more than 20 times.1 Yet little guidance is available to help patients, physicians, payers, researchers, and policy makers evaluate the quality of information derived from these nonexperimental sources.

The Agency for . . . [Full Text of this Article]

Author Affiliations: Outcome Sciences Inc, Cambridge, Massachusetts (Dr Dreyer); and Research and Development, National Institute for Health and Clinical Excellence, London, England (Dr Garner).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.